Preclinical services for biopharmaceutical product development
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N93023D00014
- Awardee
-
SIA Partners U.s., Inc. UEI M7H6L5MK9MN8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Preclinical services for biopharmaceutical product development Pre-Solicitation · 75N93022R00004 · Posted Nov 10, 2021
- Last date to order 44% complete
- IDV ceiling
- $30,000,000.00
- Maximum order
- $30,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute of Allergy and Infectious Diseases awarded a single-award indefinite-delivery contract to SIA Partners U.s., Inc. (doing business as Latham Biopharm Group) on September 8, 2023, with a ceiling of $30 million and a completion date of September 7, 2030.
The contract covers preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases across five task areas: product development planning and evaluation, analytical assay development and product characterization, process development and related activities, CGMP manufacture and related activities, and regulatory activities and documentation. Work is performed under NAICS 541711 and PSC D399.
The originating solicitation, posted in November 2021, indicated NIAID's intent to award multiple IDIQs under this program; however, this award represents a single-award vehicle. The seven-year ordering period runs from January 2023 through September 2030. The contract supports the advancement of therapeutic and diagnostic candidates through preclinical development, with a focus on preparing submissions to the Food and Drug Administration and advancing NIAID's mission in understanding, treating, and preventing infectious diseases.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Novation Agreement | $0 | |
| Novation Agreement | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N93023D00014?
75N93023D00014 was awarded to SIA Partners U.s., Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 8, 2023.
How much is contract 75N93023D00014 worth?
75N93023D00014's own ceiling is $30,000,000. A single order can be worth up to $30,000,000.
Who can order from contract 75N93023D00014?
75N93023D00014 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N93023D00014 competed?
The extent of competition for 75N93023D00014 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV